Ashwagandha for Sleep and Stress: A Systematic Evidence Review

Ashwagandha shows its clearest benefit in sleep itself, especially overall sleep quality. Across 8 studies and 1525 participants, pooled sleep-quality effects were large on paper and consistently favored treatment (pooled effect 1.13, 95% CI 0.70 to 1.56), with about 1 in 5 people gaining a meaningful benefit beyond placebo. In native terms, the average improvement was about a 1.8-point drop on the PSQI, a 21-point scale where 3 points is usually the threshold for a clearly noticeable change. That means the average person is likely to feel somewhat better sleep, but not always enough to qualify as a major clinical shift.^5812161920

That sleep-quality signal is real, but it is not equally strong in every setting. Heterogeneity, which means the studies disagree about effect size rather than direction alone, was high for this outcome (I-squared 84.6%). The prediction interval, which estimates where a future comparable study might land, crossed no effect. In plain terms, benefit is likely real on average, but some future trials could show only a small gain or none at all. That matches the study pattern: some trials found modest changes, such as a 1.5-point PSQI advantage after 90 days and a 1.6-point change-from-baseline advantage at 60 days, while others reported much larger shifts on Likert sleep scales and athlete recovery sleep items.^815161920

Ashwagandha also likely helps people fall asleep faster, but this conclusion rests mostly on one insomnia trial rather than a broad literature. In that study, sleep onset latency improved by about 5 minutes, which is larger than the usual threshold considered meaningful for insomnia trials, and the standardized effect was moderate (about 29.0 minutes vs 34.0 minutes at 10 weeks; effect size 0.53).[^^5]

Ashwagandha may modestly lengthen sleep and reduce overnight wakefulness, but those findings are less secure than the overall sleep-quality story. The available objective data suggest about 19 extra minutes of total sleep and about 7 fewer minutes awake after sleep onset. Both changes move in a helpful direction, but the sleep-duration gain falls short of the usual 30-minute threshold for a clearly felt change, and neither measure cleanly separated from placebo in the key actigraphy study (311.6 vs 292.4 minutes, p=0.076; 33.1 vs 40.0 minutes awake, p=0.076).⁵

Sleep efficiency is promising, but still early. The pooled signal suggests a moderate improvement, and in the main actigraphy study sleep efficiency reached 83.5% with ashwagandha versus 79.7% with placebo, a gap of almost 4 percentage points (p<0.0001). Still, this outcome remains low-certainty because it relies on very limited data and shows enough between-study inconsistency to make the typical effect uncertain.⁵

The big picture is that people usually report sleeping better, while objective sleep architecture is supported by only a small number of measurements. That pattern is common in supplement research: broad subjective improvement appears first, and the finer-grained device outcomes take longer to replicate. Here, the broader sleep-quality literature is already fairly convincing, while the architecture story still needs more than one or two well-performing trials.^57812161920

Ashwagandha appears to ease felt stress more convincingly than it treats broad anxiety symptoms. Across 10 studies and 1490 participants, perceived stress improved by about 5.4 points on the Perceived Stress Scale, a change that is more than double the usual 2.5-point threshold for noticeable improvement. On average, that is a meaningful reduction, and roughly 2 in 5 people achieved a benefit beyond placebo large enough to matter in daily life.^{1268111214171920}

That said, the stress literature is not as stable as the average effect first suggests. Heterogeneity was high (I-squared 88.7%), publication-bias testing suggested possible small-study inflation, and the prediction interval crossed no effect. In plain language, many studies show benefit, but they do not agree on how big that benefit usually is, and the most dramatic estimates often come from small trials. The range is wide: one 2023 trial reported a striking 9.7-point advantage on the PSS at 60 days, while a 2023 study in overweight adults found almost identical improvement in the ashwagandha and placebo groups despite both groups feeling much less stressed by the end (12.16 vs 12.70, p=0.867).¹⁰¹¹

The more typical pattern is moderate improvement rather than miracle-level change. Examples include a 4.5-point change advantage over placebo after 8 weeks in chronically stressed adults, a 4.7-point advantage in a 2026 multicenter trial, and roughly 2.5 to 5-point differences in newer sustained-release or low-dose formulations.^2161920 Those are clinically believable effects and easier to trust than the most extreme reports.^2161920

Anxiety symptoms also improve on average, but the case is weaker than for perceived stress. Across 7 studies and 1311 participants, the pooled effect was positive, and the average native-unit change was about 3 points on the Hamilton Anxiety Rating Scale, a clinician-rated scale where about 3.5 points is usually considered clinically important. That puts the average benefit near the line of noticeable improvement, but not clearly beyond it.^456111416

The main reason for caution is that anxiety results vary even more than stress results. Heterogeneity was extreme (I-squared 93.5%), and the prediction interval crossed no effect. Some trials reported large or very large effects, including Shoden studies with HAM-A scores falling from the mid-20s to around 10 after 60 days, while other trials found smaller changes or no significant difference at all, such as the GHQ-28 anxiety outcome in healthy women.⁹¹⁴ This pattern suggests ashwagandha may work best as a stress-buffering aid in people under clear strain, not as a uniformly reliable intervention for anxiety across all populations and scales.^4561114

Broader psychological distress is still underdeveloped. One trial found only a favorable trend on the DASS-21 total score without clear statistical separation from placebo, so the current analysis only offers a faint early signal here.⁴

Menopause-related psychological symptoms are more encouraging, but still too narrow to generalize widely. In one low-risk trial, menopausal women taking 300 mg twice daily improved by 5.7 points on the Menopause Rating Scale psychological subscale versus 0.25 with placebo over 8 weeks, alongside a 13.2-point advantage on the PSS.¹⁷ That is a strong result within that population, but it is still one study, so it supports possibility rather than a settled estimate of typical effect.¹⁷